- Previous Chairman Hubert Birner to Remain on Board, Olivier Litzka to Step Down
Berlin, Germany, September 29, 2017 - NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), today announced changes to its Supervisory Board. Current Board member Don deBethizy, Ph.D., has been elected new Chairman of the Supervisory Board; former Chairman Hubert Birner, Ph.D., will remain a member of the Board; and current Board member Olivier Litzka, Ph.D., will step down from the Board with effect as of the end of September 30, 2017.
Dr. deBethizy joined the NOXXON Board in 2014, providing more than 30 years of leadership experience in the biotech and pharma industry having served as CEO, Chairman and Board member for various public and private companies both in the US and EU. Dr. Birner, Managing Partner at TVM Capital and noted international entrepreneur, joined the NOXXON Board in June 2015 and had been Chairman of the Board since July 2015. Dr. Litzka, partner with Paris-based Edmond de Rothschild Investment Partners and experienced venture capitalist, had been a Board member since 2007.
“NOXXON enjoys the support of an outstanding and deeply supportive Supervisory Board and we welcome Don into the Chairman position,” said Aram Mangasarian, Ph.D., CEO of NOXXON. “We benefited tremendously from Hubert’s guidance as Chairman and I am very pleased that he remains on the Board to support this next phase of NOXXON’s development. I want also to extend a great deal of thanks to Olivier for his tireless commitment to the company over the years.”
“NOXXON has reached a very exciting juncture with the development of its lead program NOX-A12 and the ongoing clinical program that seeks to enable greater therapeutic impact for treating pancreatic and colorectal cancer patients,” said Don deBethizy, Ph.D., NOXXON’s new Chairman of the Board. “I look forward to continuing to work with Aram, his team and the Board to transform NOXXON into an exciting immune-therapy company and to realize the full potential of this unique technology alone and in high profile industry partnerships.”
Dr. deBethizy joined NOXXON’s Board of Directors in November 2014 as an independent member. He is currently President of White City Consulting ApS in Denmark and serves on the supervisory Boards of arGEN-X NV (Euronext Brussels/NASDAQ), Newron Pharmaceuticals S.P.A. (SIX Swiss Exchange), Proterris and Albumedix. He also served as Chairman of the Board of immuno-oncology company Rigontec GmbH until its acquisition by MSD in September 2017 and Board member of Serendex Pharmaceuticals A/S (Oslo Stock Exchange) until its acquisition by Savara Pharmaceuticals. Dr. deBethizy has been involved in the formation, management and financing of several successful companies both in the US and the EU. He was President and CEO of Santaris Pharma A/S until the company was sold to Roche and Executive Chairman of Contera Pharma ApS until it was sold to Bukwang Pharma in November 2014. He was also co-founder and CEO of Targacept, Inc., a public US biotechnology company listed on NASDAQ. Dr. deBethizy holds a MS and Ph.D. in toxicology from Utah State University and is a Diplomat of the American Board of Toxicology.
Note that all above-mentioned Supervisory Board affiliations that relate to a date before September 2016 refer to NOXXON Pharma AG prior to the Corporate Reorganization described in greater detail in the Information Document dated September 27, 2016 and the Prospectus dated July 10, 2017.
For more information, please contact
NOXXON Pharma N.V.
Aram Mangasarian, Ph.D., Chief Executive Officer
Tel. +49 (0) 30 726 247 0
MC Services AG
Raimund Gabriel, Managing Partner
Tel. +49 (0) 89 210228 0
Gretchen Schweitzer or Stephanie May
Tel. +49 (0) 89 2424 3494 or +49 (0) 172 861 8540
Tel. +33 (0) 1 44 71 98 55
NOXXON’s oncology-focused pipeline acts on the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor micro-environment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOX-A12 will deliver top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in 2018. Further information can be found at: www.noxxon.com
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.